Cargando…

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis

Detalles Bibliográficos
Autores principales:	Guy, Alexandre, Danaee, Anicee, Paschalaki, Koralia, Boureau, Lisa, Rivière, Etienne, Etienne, Gabriel, Mansier, Olivier, Laffan, Michael, Sekhar, Mallika, James, Chloe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306304/ https://www.ncbi.nlm.nih.gov/pubmed/32647794 http://dx.doi.org/10.1097/HS9.0000000000000364

Ejemplares similares

Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2(V617F) mutation
por: Guy, Alexandre, et al.
Publicado: (2023)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
por: Allain-Maillet, Sophie, et al.
Publicado: (2020)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

JAK2V617F: Is It Sufficient as a Single Player in Splanchnic Venous Thrombosis?
por: Dhiman, Pratibha, et al.
Publicado: (2015)

JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders
por: McLornan, Donal, et al.
Publicado: (2006)

Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms
por: Stein, Brady L., et al.
Publicado: (2011)

Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha
por: Lane, Steven W., et al.
Publicado: (2013)

Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms
por: ZHANG, SHU-PENG, et al.
Publicado: (2015)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
por: Ferdowsi, Shirin, et al.
Publicado: (2016)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022)

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013)

JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms
por: Elf, Shannon E.
Publicado: (2021)

JAK2V617F mRNA metabolism in myeloproliferative neoplasm cell lines
por: Nauroy, P, et al.
Publicado: (2014)

Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
por: Shi, Kaiyao, et al.
Publicado: (2014)

The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Reversine exhibits antineoplastic activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Lima, Keli, et al.
Publicado: (2019)

Hematopoietic fitness of JAK2(V617F) myeloproliferative neoplasms is linked to clinical outcome
por: Abu-Zeinah, Ghaith, et al.
Publicado: (2022)

The JAK2 V617F mutation in isolated neutropenia
por: Langabeer, Stephen E.
Publicado: (2018)

Metformin exerts multitarget antileukemia activity in JAK2(V617F)-positive myeloproliferative neoplasms
por: Machado-Neto, João Agostinho, et al.
Publicado: (2018)

The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms
por: Zhan, H, et al.
Publicado: (2018)

Expression of CD markers in JAK2(V617F) positive myeloproliferative neoplasms: Prognostic significance
por: Shahrabi, Saeid, et al.
Publicado: (2018)

Erythrocyte-derived microvesicles induce arterial spasms in JAK2(V617F) myeloproliferative neoplasm
por: Poisson, Johanne, et al.
Publicado: (2020)

Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2(V617F) mutation
por: Fan, Wenjuan, et al.
Publicado: (2023)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
por: Yönal-Hindilerden, İpek, et al.
Publicado: (2023)

Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series
por: Greenfield, Graeme, et al.
Publicado: (2018)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

The implication of identifying JAK2(V617F) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis
por: Olsen, Randall J., et al.
Publicado: (2008)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
por: Kalala, Fani, et al.
Publicado: (2012)

Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
por: Kim, Hye-Ran, et al.
Publicado: (2013)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
por: Belcic Mikic, Tanja, et al.
Publicado: (2019)

Soluble interleukin-6 receptor in patients with JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Garbers, Christoph, et al.
Publicado: (2020)

Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm
por: Pedersen, Kasper Mønsted, et al.
Publicado: (2020)

JAK2 p.(V617F) mutation in Tunisian myeloproliferative neoplasms and its genotype-phenotype correlation
por: Sassi, Hela, et al.
Publicado: (2021)

P1046: SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Novak, W., et al.
Publicado: (2022)

The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
por: Orbell, Lai Yee, et al.
Publicado: (2023)

JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
por: Syeed, Nidda
Publicado: (2019)

JAK2 V617F and the evolving paradigm of polycythemia vera
por: Means, Robert T.
Publicado: (2010)

Hemochromatosis, Erythrocytosis and the JAK2 p.V617F Mutation
por: Langabeer, Stephen E.
Publicado: (2017)

The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective
por: Staerk, Judith, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_90epevm685u1hgcva8lnmncoht